Deucravacitinib Shows Superior Efficacy Over Placebo, Apremi

Response rates were greater with deucravacitinib vs placebo or apremilast at 16 weeks in patients with moderate to severe scalp psoriasis, according to one study.

Related Keywords

United States , American , , Journal Of The American Academy Dermatology , American Academy , Physician Global Assessment , Psoriasis Scalp Severity , Long Term Efficacy Of Deucravacitinib , Deucravacitinib Scalp Psoriasis Efficacy , Scalp Psoriasis Treatment Study , Moderate To Severe Psoriasis Response Rates , Deucravacitinib Vs Apremilast In Psoriasis ,